Table 1.
Characteristics of study groups.
| Study Groups (n = 335) | ||||
|---|---|---|---|---|
| Characteristic | ATB (n = 40) | P-LTBI (n = 75) | H-LTBI (n = 70) | HC (n = 150) |
| Median (IQR) age (yr) | 53 (41–63) | 57 (51–63) | 43 (36–52) | 30 (26–34) |
| Male subjects, No. (%) | 23 (57.5) | 47 (62.7) | 25 (35.7) | 31 (20.7) |
| M. tuberculosis culture and PCR result, No. (%) | ||||
| Culture positive/PCR positive | 9 (22.5) | NA | NA | NA |
| Culture negative/PCR positive | 8 (20.0) | NA | NA | NA |
| Culture positive/PCR negative | 23 (57.5) | NA | NA | NA |
| Manifestation of ATB, No. (%) | ||||
| Active pulmonary disease with or without extra-pulmonary TB | 33 (82.5) | NA | NA | NA |
| Solely extra-pulmonary TB (Lymph node, colon nasopharynx, soft tissue, bone) | 7 (17.5) | NA | NA | NA |
| Previous anti-tuberculosis medication, No. (%) | 27 (67.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Median duration (range) of TB treatment before blood sampling, days (range) | 12 (2–30) | NA | NA | NA |
| Underlying conditions, No. (%) | ||||
| Solid organ failure (liver, kidney) | 0 (0.0) | 37 (49.3) | 0 (0.0) | 0 (0.0) |
| Hematologic malignancy | 0 (0.0) | 6 (8.0) | 0 (0.0) | 0 (0.0) |
| Systemic autoimmune disease | 0 (0.0) | 32 (42.7) | 0 (0.0) | 0 (0.0) |
| ALC on the day of IGRA, median (range), /μl | 1480 (810–3190) | 1640 (50–3980) | 1990 (1110–2860) | 1890 (800–3250) |
Abbreviation: ATB, active tuberculosis; P-LTBI, patients with immunocompromised status and latent TB infection; H-LTBI, health care workers with latent TB infection; HC, health care workers confirmed with previous negative IGRA and low risks; PCR, polymerase chain reaction; TB, M. tuberculosis; ALC, Absolute lymphocyte counts.